XML 54 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share-Based Payments
3 Months Ended
Jul. 31, 2012
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 4. Share-Based Payments

 

The Company has in place a 2010 Equity Incentive Plan, a 2008 Equity Incentive Plan, and a Director Compensation Plan of 2010. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.

 

Stock-based compensation in the amount of $739,000 and $1,014,000 was recognized for the three months ended July 31, 2012 and 2011, respectively.  Stock-based compensation expense was recognized as follows (in thousands):

 

    Three Months Ended July 31,  
    2012     2011  
             
General and administrative     570       916  
Sales and marketing     82       74  
Research and development     24       24  
TOS cost of sales     8       -  
POS cost of sales     55       -  
                 
Total stock-based compensation expense     739       1,014  

 

Stock Option Grants

 

Black-Scholes assumptions used to calculate the fair value of options granted during the three months ended July 31, 2012 were as follows:

 

 The weighted average fair value of stock options granted during the three months ended July 31, 2012 and 2011 was $0.54 and $0.74, respectively. The Company’s stock options activity for the three months ended July 31, 2012 is as follows:

 

Expected term in years     6.0  
Risk-free interest rates      0.8% to 0.9  %
Volatility      98.5% to 98.8  %
Dividend yield     0 %

 

                            Weighted        
                      Weighted     Average        
          Directors           Average     Remaining     Aggregate  
    Non-     and           Exercise     Contractual     Intrinsic  
    Employees     Employees     Total     Price     Life (Years)     Value  
                                     
Outstanding, May 1, 2012     1,410,000       13,456,038       14,866,038     $ 0.88       7.6     $ -  
Granted     15,000       236,250       251,250       0.57                  
Exercised     -       -       -       -                  
Forfeited     -       -       -       -                  
Expired     -       (13,333 )     (13,333 )     0.95                  
Change in employee status     -       -       -       -                  
                                                 
Outstanding, July 31, 2012     1,425,000       13,678,955       15,103,955       0.87       7.4       -  
                                                 
Vested and expected to                                                
vest as of July 31, 2012     1,425,000       13,678,955       15,103,955       0.87       7.4       -  
                                                 
Exercisable as of                                                
July 31, 2012     1,248,333       7,711,677       8,960,010       0.88       6.7       -  

 

Restricted Stock Grants

 

A summary of the activity related to restricted stock grants is as follows:

 

            Weighted  
            Average  
            Grant Date  
      Total     Fair Value  
      Shares     Per Share  
               
  Nonvested, May 1, 2012       25,000     $ 0.75  
  Granted       -       -  
  Vested       (12,500 )     0.75  
  Forfeited       -       -  
  Expired       -       -  
                     
  Nonvested as of July 31, 2012       12,500       0.75  

  

The aggregate fair value of shares vested during the three months ended July 31, 2012 and 2011 was $5,000 and $43,000, respectively.

 

Stock Purchase Warrants

 

As of July 31, 2012, the Company had warrants outstanding for the purchase of 1,416,667 shares of its common stock, all of which were exercisable.  Of these warrants, 1,266,667 were issued in connection with the April 2011 financing arrangement and are accounted for as liabilities as further discussed in Note 5.  The weighted average exercise price of all warrants outstanding is $0.91. As of July 31, 2012 and April 30, 2012, these warrants had no intrinsic value and had weighted average remaining contractual lives of 3.6 and 3.8 years, respectively.